Treatment of canine fucosidosis by intracisternal enzyme infusion

Experimental Neurology

Volumn 230, Issue 2, 2011, Pages 218-226

  Kondagari, Gauthami S ^a,d   King, Barbara M ^b   Thomson, Peter C ^a   Williamson, Peter ^a   Clements, Peter R ^c   Fuller, Maria ^b   Hemsley, Kim M ^b   Hopwood, John J ^b   Taylor, Rosanne M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Lysosomal Diseases Research Unit   (Australia)

^c Genetics and Molecular Pathology   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Canine fucosidosis; Central nervous system; Cerebrospinal fluid; Intracisternal enzyme replacement therapy; Lysosomal storage disease; Tandem mass spectrometry

Indexed keywords

OLIGOSACCHARIDE; RECOMBINANT ALPHA LEVO FUCOSIDASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CERVICAL LYMPH NODE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; ENZYME ACTIVITY; ENZYME REPLACEMENT; FUCOSIDOSIS; INFLAMMATION; INJECTION SITE; LIVER; LUMBAR SPINAL CORD; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; THORACIC SPINAL CORD; WEIGHT GAIN;

ALPHA-L-FUCOSIDASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; FUCOSIDOSIS; INFUSIONS, INTRAVENTRICULAR; MASS SPECTROMETRY; SPINAL CORD; TREATMENT OUTCOME;

EID: 79958760219     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.04.019     Document Type: Article

References (30)

1. Abraham D., Blackmore W.F., Dell A., Herrtage M.E., Jones J., Littlewood J.D., Oates J., Palmer A.C., Sidebotham R., Winchester B. Biochemical evidence for a case of canine fucosidosis. Biochem. Soc. Trans. 1984, 12:2031-2032.
2. Auclair D., Finnie J., White J., Nielsen T., Fuller M., Kakkis E., Cheng A., O'Neill C.A., Hopwood J.J. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol. Genet. Metab. 2010, 99:132-141.
3. Bielicki J., Muller V., Fuller M., Hopwood J.J., Anson D.S. Recombinant canine alpha-l-fucosidase: expression, purification, and characterization. Mol. Genet. Metab. 2000, 69:24-32.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
5. Chang M., Cooper J.D., Sleat D.E., Cheng S.H., Dodge J.C., Passini M.A., Lobel P., Davidson B.L. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 2008, 16:649-656.
6. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E., Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
7. Dickson P.I., Hanson S., McEntee M.F., Vite C.H., Vogler C.A., Mlikotic A., Chen A.H., Ponder K.P., Haskins M.E., Tippin B.L., Le S.Q., Passage M.B., Guerra C., Dierenfeld A., Jens J., Snella E., Kan S., Ellinwood N.M. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol. Genet. Metab 2010, 101:115-122.
8. Dodge J.C., Clarke J., Treleaven C.M., Taksir T.V., Griffiths D.A., Yang W.D., Fidler J.A., Passini M.A., Karey K.P., Schuchman E.H., Cheng S.H., Shihabuddin L.S. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp. Neurol. 2009, 215:349-357.
9. Ferrara M.L., Occhiodoro T., Fuller M., Hawthorne W.J., Teutsch S., Tucker V.E., Hopwood J.J., Stewart G.J., Anson D.S. Canine fucosidosis: a model for retroviral gene transfer into haematopoietic stem cells. Neuromuscul. Disord. 1997, 7:361-366.
10. Healy P.J., Farrow B.R., Nicholas F.W., Hedberg K., Ratcliffe R. Canine fucosidosis: a biochemical and genetic investigation. Res. Vet. Sci. 1984, 36:354-359.
11. Hemsley K.M., King B., Hopwood J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 2007, 90:313-328.
12. Hemsley K.M., Beard H., King B.M., Hopwood J.J. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Genes Brain Behav. 2008, 7:740-753.
13. Hemsley K.M., Norman E.J., Crawley A.C., Auclair D., King B., Fuller M., Lang D.L., Dean C.J., Jolly R.D., Hopwood J.J. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-A proof of principle study. Mol. Genet. Metab. 2009, 98:383-392.
14. Kakkis E., McEntee M., Vogler C., Le S., Levy B., Belichenko P., Mobley W., Dickson P., Hanson S., Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 2004, 83:163-174.
15. Kaneko J. Clinical Biochemistry of Domestic Animals 1989, Department of Clinical Pathology, School Of Veterinary Medicine, University Of California, Davis, California. 4th ed.
16. Kondagari G.S., Yang J., Taylor R.M. Investigation of cerebrocortical and cerebellar pathology in canine fucosidosis and comparison to aged brain. Neurobiol. Dis. 2011, 41:15-23.
17. Kondagari G.S., Ramanathan P., Taylor R. Canine fucosidosis: a neuroprogressive disorder. Neurodegener. Dis. 2011, 8:240-251.
18. Krivit W., Peters C., Shapiro E.G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol. 1999, 12:167-176.
19. Lee W.C., Tsoi Y.K., Troendle F.J., DeLucia M.W., Ahmed Z., Dicky C.A., Dickson D.W., Eckman C.B. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 2007, 21:2520-2527.
20. Marshall N.R., Jolly R.D., Hartman A., Hemsley K.M., Leanne W.K., Hannoyche H. Intracisternal enzyme replacement therapy: the effect of post therapy posture. Proceedings of the 11th meeting of the mucopolysaccharidosis society 2010, 2010101.
21. Matzner U., Matthes F., Weigelt C., Andersson C., Eistrup C., Fogh J., Gieselmann V., Matzner U., Matthes F., Weigelt C., Andersson C., Eistrup C., Fogh J., Gieselmann V. Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease. J. Mol. Med. 2008, 86:433-442.
22. Munoz-Rojas M.V., Vieira T., Costa R., Fagondes S., John A., Jardim L.B., Vedolin L.M., Raymundo M., Dickson P.I., Kakkis E., Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am. J. Med. Genet. 2008, 146:2538-2544.
23. Munoz-Rojas M.V., Horovitz D.D., Jardim L.B., Raymundo M., Llerena J.C., de Magalhaes Tde S., Vieira T.A., Costa R., Kakkis E., Giugliani R. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol. Genet. Metab. 2010, 99:346-350.
24. Occhiodoro T., Hopwood J.J., Morris C.P., Anson D.S. Correction of alpha-L-fucosidase deficiency in fucosidosis fibroblasts by retroviral vector-mediated gene transfer. Hum. Gene Ther. 1992, 3:365-369.
25. Pomroy, S., 2002. Canine fucosidosis experimental treatment by enzyme replacement therapy. Thesis submitted to University of sydney.
26. Sivakumur P., Wraith J.E. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J. Inherit. Metab. Dis. 1999, 22:849-850.
27. Taylor R.M., Farrow B.R.H., Healy P.J. Canine fucosidosis-clinical findings. J. Small Anim. Pract. 1987, 28:291-300.
28. Taylor R.M., Farrow B.R., Stewart G.J., Healy P.J., Tiver K. The clinical effects of lysosomal enzyme replacement by bone marrow transplantation after total lymphoid irradiation on neurologic disease in fucosidase deficient dogs. Transplant. Proc. 1988, 20:89-93.
29. Taylor R.M., Farrow B.R., Stewart G.J. Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs. Am. J. Med. Genet. 1992, 42:628-632.
30. Vellodi A., Cragg H., Winchester B., Young E., Young J., Downie C.J., Hoare R.D., Stocks R., Banerjee G.K. Allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant. 1995, 15:153-158.